Abstract
This new agent became known as “Liquid Ecstasy, Liquid E, Liquid X, or Fantasy”. It is a central nervous system depressant, and has been used as an anxiolytic, anesthetic and sedative/hypnotic, inducing a sleep-like state in experimental animals in doses ranging from 0.1 to 1.5 g/kg [5]. GHB is also a putative neurotransmitter [6]. Treatment with GHB has been shown to affect many neurotransmitter systems, most notably, dopamine, glutamate and acetylcholine [7]. A number of early studies focused on GHB’s action at dopaminergic synapses and showed that GHB initially inhibits dopamine release and then, time-dependently, causes its release [8]. Importantly, GHB exhibits an extremely high affinity for a specific GHB receptor [9]. This GHB receptor is a novel G-protein coupled receptor [10], which is widely distributed throughout the cortex and certain subcortical locations, most notably the hippocampus, amygdala, septum, basal ganglia and substantia nigra [11]. It is obvious that GHB receptors mediate some of GHB’s action because cortical neurons, which are normally activated by GHB revert to their normal activity levels when GHB is added, along with its selective receptor antagonist NCS-3827 [11a]. The recent development of truly selective GHB receptor agonists has allowed scientists to finally understand GHB’s mechanism. At low doses, GHB is binding almost exclusively to the GHB receptor, a receptor, which through pathways not yet understood, stimulates the release of glutamate, the major excitatory neurotransmitter in the cortex. As the dose of GHB increases, more and more GHB binds to, and activates the inhibitory GABAB receptor. This leads to the sedative/hypnotic effect of GHB. GHB’s dose-response curve is similar to that of alcohol. At higher doses, users fall unconscious and are temporarily unable to be awakened (coma). It also may dangerously depress breathing, therefore mixing with alcohol should be avoided.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tunnicliff G. Significance of γ-hydroxybutyric acid in the brain. Gen Pharmacol. 1992;23:1027–34.
Castelli MP, Ferraro L, Mocci I, Carta F, Carai MA, Antonelli T, et al. Selective gamma-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of gamma-hydroxybutyric acid. J Neurochem. 2000;87:722–32.
Spanos PF, Tagliamonte A, Tagliamonte P, Gessa GL. Stimulation of brain dopamine synthesis by g-hydroxybutyrate. J Neurochem. 1971;18:1831–6.
Feigenbaum JJ, Howard SG. Does gamma-hydroxybutyrate inhibit or stimulate central DA release? Int J Neurosci. 1996;88:53–69.
Tunnicliff G. Sites of action of gamma-hydroxybutyrate – a neuroactive drug with abuse potential. J Toxicol Clin Toxicol. 1997;35:581–90.
Andriamampandry C, Taleb O, Viry S, Muller C, Humbert J, Gobaille S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma hydroxybutyrate. FASEB. 2003;17:1691–3.
Hechler V, Gobaille S, Maitre M. Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography. Brain Res. 1992;572:345–8.
Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol. 1964;3:433–52.
Bessman SP, Fishbein WN. Gamma-hydroxybutyrate, a normal brain metabolite. Nature. 1963;200:1207–8.
Root B. Oral premedication of children with 4-hydroxybutyrate. Anesthesiology. 1965;26:259–60.
Winters WD, Spooner CE. Various seizure activities following gamma-hydroxybutyrate. Int J Neuropharmacol. 1965;4:197–200.
Godschalk M, Dzoljic MR, Bonta IL. Slow wave sleep and a state resembling absence epilepsy induced in the rat by g-hydroxybutyrate. Eur J Pharmacol. 1977;44:105–11.
Solway J, Sadove MS. 4-Hydroxybutyrate: a clinical study. Anesth Analg. 1965;44:532–9.
Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate: a review of clinical and sleep laboratory findings. Sleep. 1986;9:285–9.
Takahara J, Yunoki S, Yakushiji W, Yamauchi J, Yamane Y, Ofuji T. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab. 1977;44:1014–7.
Gallimberti L, Canton G, Gentile N, et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet. 1989;2:787–9.
Gallimberti L, Cibin M, Pagnin P, et al. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. Neuropsychopharmacology. 1993;9:77–81.
WHO questionnaire for review of dependence-producing psychoactive substances, 2000.
Sanguineti VR, Angelo A, Frank MR. GHB: a home brew. Am J Drug Alcohol Abuse. 1997;23:634–42.
Wiley J, Dick R, Arnold T. Hematuria from home-manufactured GHB. J Toxicol Clin Toxicol. 1998;46:502–3.
Henretig F, Vassalluzo C, Osterhoudt K, et al. “Rave by net”: gamma-hydroxybutyrate toxicity from kits sold to minors via the internet. J Toxicol Clin Toxicol. 1998;36:503.
Palatini P, Tedeschi L, Frison G, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol. 1993;45:353–6.
Ferrara SD, Zotti S, Tedeschi L, et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol. 1992;34:231–5.
Scharf MB, Lai AA, Branigan B, Stover R, Berkowitz DB. Pharmacokinetics of gamma-hydroxybutyrate in narcoleptic patients. Sleep. 1998;21:507–14.
Helrich M, McAslan TC, Skolnik S, Bessman SP. Correlation of blood levels of 4-hydroxybutyrate with state of consciousness. Anesthesiology. 1964;25:771–5.
Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Encephale. 1980;6:93–9.
Vickers MD. Gamma-hydroxybutyric acid. Int Anesthesiol Clin. 1969;7:75–89.
Lettieri J, Fung H. Absorption and first-pass metabolism of (14)C-gamma-hydroxybutyric acid. Res Commun Chem Pathol Pharmacol. 1976;13:435–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2009 Springer Science + Business Media B.V.
About this chapter
Cite this chapter
Freye, E. (2009). Gamma-Hydroxybutyric (GHB) Acid. In: Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2448-0_28
Download citation
DOI: https://doi.org/10.1007/978-90-481-2448-0_28
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2447-3
Online ISBN: 978-90-481-2448-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)